Apidra Solostar

Manufacturer: Sanofi-Aventis, France

Pharmaceutical name: Insulin Glulisine

Pack: 1 box (5 pens x 3ml (100 iu/ml))

Apidra Solostar is a fast-acting insulin analog designed to enhance glycemic control in adults with type 2 diabetes and in adults and children (ages 4 and older) with type 1 diabetes.

 

When utilized as a mealtime insulin, Apidra Solostar should be administered within 15 minutes prior to or within 20 minutes after beginning a meal. This insulin, administered via subcutaneous injection, is typically incorporated into treatment regimens that include a longer-acting insulin.

 

Apidra Solostar is not suitable for use during hypoglycemic events and in individuals who are hypersensitive to Apidra or any of its components. Insulin pens, needles, or syringes must not be shared among patients. Never reuse needles.

 

All patients receiving insulin should have their blood glucose levels monitored closely. Adjustments to insulin regimens should be made cautiously and only under medical supervision. Changes in insulin strength, brand, type, or delivery method may necessitate adjustments to the insulin dose or accompanying oral antidiabetic medications. As is the case with all insulin formulations, the onset and duration of Apidra’s action can differ among individuals or at various times for the same individual, influenced by factors such as the injection site, local blood flow, or ambient temperature.

 

Hypoglycemia is the most frequently encountered side effect of insulin therapy, including Apidra, and can be severe.

 

Severe, life-threatening, generalized allergic reactions, including anaphylaxis, may occur. All insulins, including Apidra Solostar, have the potential to induce hypokalemia, which can be serious if left untreated.

 

A reduction in the Apidra Solostar dosage may be necessary for patients with kidney or liver impairment.

 

Apidra Solostar for subcutaneous use should not be mixed with any insulins other than NPH. It should not be combined with any insulin when used in a pump or for intravenous administration.

 

Concurrent use of thiazolidinediones (TZDs) and insulin may lead to fluid retention and heart failure. Monitor for symptoms of heart failure, and consider reducing or stopping TZD treatment if such symptoms arise.

 

Certain medications may influence glucose metabolism, necessitating insulin dose adjustments and close blood glucose monitoring. The symptoms of hypoglycemia could be diminished in patients taking anti-adrenergic medications (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

 

Common side effects associated with Apidra Solostar include reactions at the injection site, lipodystrophy, itching, and rashes.